SCHEMBL8094095

SCHEMBL8094095

Cc1cc(OC2CCN(Cc3ccc(O)cc3F)CC2)c2cccc(F)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 2/20 0.40
GRIN2B Q13224 2/20 0.40
ADRB2 P07550 1/20 0.39
HRH3 Q9Y5N1 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
KCNH2 Q12809 4/20 0.37
SCN5A Q14524 3/20 0.37
SCN9A Q15858 3/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
PDE4B Q07343 1/20 0.36
SCN1A P35498 2/20 0.36
SCN8A Q9UQD0 2/20 0.36
ADRA1A P35348 1/20 0.36
AR P10275 1/20 0.36
HTR2C P28335 1/20 0.36
HTR7 P34969 1/20 0.36
HTR2B P41595 1/20 0.36
HTR3A P46098 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8095680 0.89 PDE4B (0.46) ALDH1A1KCNH2SCN5ASCN9AKMT2A
SCHEMBL8104328 0.89 PDE2A (0.43) ADRB2HRH3ALDH1A1TDP1PDE4B
SCHEMBL4246391 0.89 SCN1A (0.42) HRH3SCN1ASCN8A
SCHEMBL13945393 0.88 ADRB2 (0.51) ADRB2HRH3ALDH1A1KMT2AMEN1
SCHEMBL8095861 0.85 KCNH2 (0.41) HRH3ALDH1A1KCNH2SCN5ASCN9A
SCHEMBL8100325 0.85 JAK2 (0.39) HRH3ALDH1A1KCNH2SCN5ASCN9A
SCHEMBL5526683 0.83 SCN1A (0.50) KCNH2SCN5ASCN9ASCN1ASCN8A
SCHEMBL8091662 0.83 HRH1 (0.47) ALDH1A1KCNH2KMT2ASCN1ASCN8A
SCHEMBL8093682 0.82 SCN5A (0.40) ADRB2ALDH1A1TDP1KCNH2SCN5A
SCHEMBL8088026 0.81 HTR2C (0.40) PDE4BSCN1ASCN8AARHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
WO-2009000085-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS TRPV1, TRPV2, TRPA1 GRIN1 109/4885GRIN2B 80/4885ADRB2 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.